News

CMN Weekly (14 October 2022) - Your Weekly CRISPR Medicine News

Some of the best links we picked up around the internet

By: Gorm Palmgren - Oct. 14, 2022

Top picks

  • American researchers have used cross-species evolution to engineer a highly potent AAV variant for therapeutic gene transfer and genome editing. The variant, AAV.cc47, shows improved attributes benchmarked against AAV serotype 9 as evidenced by robust reporter and therapeutic gene expression, Cre recombination and CRISPR genome editing in normal and diseased mouse models. Furthermore, AAV.cc47 vectors are also efficient in macaques and pigs, suggesting that they might improve predictive modelling in preclinical studies and clinical translatability by broadening the therapeutic window of AAV-based gene therapies.
  • Italian researchers have used CRISPR-Cas9 to delete the IL30 gene that promotes prostate cancer (PC) onset and development. Deletion of IL30 in PC cells dramatically downregulated several oncogenes, whereas tumour suppressors, primarily SOCS3, were upregulated. The authors suggest that the efficacy of CRISPR-Cas9-mediated targeting of IL30 in curbing PC progression paves the way for its clinical use.

Research

Industry

Detection

Reviews

News from CRISPR Medicine News

To get more of the CRISPR Medicine News delivered to your inbox, sign up to the free weekly CMN Newsletter here.

Tags

HashtagArticleHashtagMissing linksHashtagNewsHashtagCMN Weekly

News: CMN Weekly (14 October 2022) - Your Weekly CRISPR Medicine News
Search your next CRISPR job here...
Search your next CRISPR job here...
CLINICAL TRIALS
Solid Tumors (NCT03970382)
Sponsors:
PACT Pharma, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Beta-Thalassemia, BT, (NCT05442346)
Sponsors:
Bioray Laboratories
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine